<DOC>
	<DOCNO>NCT01705145</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , ivacaftor child cystic fibrosis ( CF ) 2 5 year age CF Transmembrane Conductance Regulator ( CFTR ) gate mutation least 1 allele . Part A designed evaluate safety PK multiple-dose administration ivacaftor participant 2 5 year age confirm dose Part B . Part B design evaluate safety , PK , PD , efficacy ivacaftor participant 2 5 year age .</brief_summary>
	<brief_title>Study Ivacaftor Cystic Fibrosis Subjects 2 Through 5 Years Age With CFTR Gating Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF Must CFTR gate mutation least 1 allele Aged 2 5 year screen Day 1 Weight &gt; = 8 kg screen Day 1 Hematology , serum chemistry , coagulation , vital sign result screen clinically significant abnormality would interfere study assessment , judge investigator History illness condition , opinion investigator , might confound result study pose additional risk administer study drug participant An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 4 week Day 1 Abnormal liver function , screen History solid organ hematological transplantation Use moderate strong inducer inhibitor cytochrome P450 ( CYP ) 3A within 2 week Day 1 Participation clinical study involve administration either investigational marketed drug within 30 day 5 terminal halflives screen</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>